$NVS Novartis AG has released its Q4 2024 earnings report, showcasing solid growth. Key metrics: EPS of $1.98 (+33%) and revenue of $13.15B (+15.14% Y/Y). Risks include anticipated generic competition impacting sales and the potential for revenue fluctuations. Highlights include a 38.7% core operating margin, with the company projecting mid-single-digit growth for 2025. Future opportunities lie in a strong pipeline and continued brand performance, including Entresto and Kisqali. For detailed insights, check http://valueverge.com/NVS.